期刊文献+

金雀异黄素通过调控miR-27a及其靶基因对卵巢癌细胞SKOV3生长的影响 被引量:3

Effects of genistein on the growth of ovarian cancer cell SKOV3 by regulating miR-27a and target gene expression
下载PDF
导出
摘要 目的:研究金雀异黄素对卵巢癌细胞株SKOV3生长的抑制作用及其可能的机制。方法:收集卵巢癌组织及良性组织,应用RT-PCR法检测miR-27a的表达。用不同浓度的金雀异黄素处理细胞,通过SRB法检测金雀异黄素单用或加入miR-27amimics后对细胞株生长的抑制作用;经RT-PCR和Western blot检测miR-27a及靶基因Sprouty2表达的变化。结果:miR-27a在卵巢癌组织中的表达高于良性组织(P<0.05)。金雀异黄素可呈浓度和时间依赖的方式抑制卵巢癌细胞SKOV3生长;金雀异黄素浓度依赖性地下调miR-27a,上调Sprouty2的表达,且miR-27amimics能够部分拮抗金雀异黄素抑制细胞生长的作用。结论:金雀异黄素可能通过下调致癌miR-27a的表达,发挥抑制卵巢癌细胞生长的作用。 AIM: To investigate the effects of genistein on the growth of ovarian cancer cell SKOV3 and potential mechanism.METHODS: The expression of the miR-27a in formalin-fixed paraffin-embedded(FFPE) ovarian cancer tissues and benign ovarian tissues were examined by RT-PCR.SKOV3 cells were treated with different concentration of genistein.Then the SRB assays were performed to assess the growth inhibition of genistein to ovarian cancer cells.RT-PCR and Western blot were used to test expression of miR-27a and Sprouty2 respectively.RESULTS:The expression levels of miR-27a in FFPE ovarian cancer tissues were significantly higher than those seen in benign ovarian tissues.Genistein could markedly decrease human ovarian cancer cell growth in time-and dose-dependent manner and downregulate the expression of miR-27a,which was accompanied by significantly increased expression of Sprouty2.CONCLUSION: Genistein has an inhibitory effect on the growth of ovarian cancer cells,which was due to the downregulation of miR-27a expression.
出处 《中国临床药理学与治疗学》 CAS CSCD 2012年第12期1321-1326,共6页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 国家自然科学基金项目(81001444 30873099 81102458 81172004)
关键词 金雀异黄素 卵巢癌 生长 miR-27a Sprouty2 Genistein Ovarian cancer Growth MiR-27a Sprouty2
  • 相关文献

参考文献22

  • 1Cragun JM. Screening for ovarian cancer [J].Canc- er Control, 2011, 18(1) :16-21.
  • 2Esquela-Kerscher A, Slack FJ. Oncomirs - microR- NAs with a role in cancer [J]. Nat Rev Cancer, 2006, 6(4):259-269.
  • 3Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors [J].Dev Biol, 2007, 302(1):1-12.
  • 4龚志成,黄琼,刘昭前.miRNA在糖尿病中的研究进展[J].中国临床药理学与治疗学,2010,15(2):214-218. 被引量:5
  • 5Zhao X, Yang L, Hu J. Down-regulation of miR- 27a might inhibit proliferation and drug resistance of gastric cancer cells [J].J Exp CIin Cancer Res, 2011,30:55.
  • 6Sun Q, Gu H, Zeng Y, et al. Hsa-mir-27a genetic variant contributes to gastric cancer susceptibility through affecting miR-27a and target gene expres- sion[J]. Cancer Sci, 2010,101 (10) : 2241 - 2247.
  • 7Farina HG, Pomies M, Alonso DF, et al. Antitu- mor and antiangiogenic activity of soy isofla,vone genistein in mouse models of melanoma and breast cancer [J]. OncolRep, 2006, 16(4):885-891.
  • 8逄晓云,沈金芳,贡沁燕.大豆异黄酮对大鼠血脂的影响及其体内外抗氧化作用研究[J].中国临床药理学与治疗学,2008,13(1):62-67. 被引量:16
  • 9Wang B, Zou Y, Li H, et al. Genistein inhibited retinal neovaseularization and expression of vascular endothelial growth factor and hypoxia inducible fac- tor 1alpha in a mouse model of oxygen-induced reti- nopathy[J]. J Ocul Pharmacol Ther, 2005, 21(2):107-113.
  • 10Pan JS, Zhu HJ, Zhang B, et al. Inhibitive effect of genistein on hypoxia-induced basic fibroblast growth factor expression in human retinal pigment epitheli- um cells[J].J Ocul Pharmacol Ther, 2006, 22(2) :103-109.

二级参考文献12

  • 1Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule [ J ]. Fed Regist, 1999, 64 (206) : 57700 - 57733.
  • 2Cooke GM. A review of the animal models used to investigate the health benefits of soy isoflavones[J]. J AOAC Int, 2006,89(4):1215- 1227.
  • 3吴葆杰,张世玲.调血脂及抗动脉粥样硬化药的筛选法[M]//徐叔云,卞如濂,陈修,主编.药理实验方法学.2版.北京:人民卫生出版社,1991:1047-1051.
  • 4韩玲译.抗动脉粥样硬化作用[M]//Vogel H G,等编著,杜冠华等译.药理学实验指南-新药发现和药理学评价.1版.北京:科学出版社,2001:777-809.
  • 5Sacks FM, Lichtenstein A, Van Horn L, et al. Soy protein, isoflavones, and cardiovascular health: an American Heart Association Science Advisory for professionals from the Nutrition Committee[J]. Circulation, 2006, 113(7) : 1034- 1044.
  • 6Yamakoshi J, Piskula MK, Izumi T, et al. Isoflavone aglycone-rich extract without soy protein attenuates atherosclerosis development in cholesterol-fed rabbits[J]. J Nutr, 2000,130(8) : 1887 - 1893.
  • 7Makela SI, Pylkkanen LH, Santti RS, et al. Dietary soybean may be antiestrogenic in male mice [ J]. J Nutr, 1995,125(3) :437 - 445.
  • 8Fuchs D, Erhard P, Turner R, et al. Genistein reverses changes of the proteome induced by oxidized-LDL in EA. hy 926 human endothelial cells [ J ]. J Proteome Res,2005,4(2):369- 376.
  • 9Rifici VA, Khachadurian AK. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol [ J ]. Metabolism, 1992,41(10) : 1110 - 1114.
  • 10Wiseman H, O' Reilly JD, Adlerereutz H, et al. Isoflavone phytoestrogens consumed in soy decrease F2-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans[J]. Am J Clin Nutr, 2000,72(2) :395 - 400.

共引文献19

同被引文献47

  • 1孙伟,范跃祖,张文忠,葛春燕,赵凤娣,周婷婷,宁艳霞.去甲斑蝥素对胆囊癌细胞体外模拟血管生成拟态的抑制作用[J].外科研究与新技术,2012,1(1):42-48. 被引量:5
  • 2马成杰,李元青,李晓明,任映,宋崇顺,陈勃,黄晓琳,陈信义.三七活性成分抑制小鼠黑色素瘤生长的实验研究[J].亚太传统医药,2007,3(4):68-70. 被引量:1
  • 3POrez-Soler R, Chachoua A, Hammond I. A, et al. Determinants of tumor response and survival with erlotinib in patients with non small-cell lung cancer [J]. J Clinoncol , 2004, 22(16): 3238-247.
  • 4Pao W, Miller V A, Politi K A, et al. Acquired re sistance of lung adenocarcinomas to gefitinib or erlo- tinib is associated with a second mutation in the EG- FR kinase domain[J]. PLoS medicine, 2005, 2(33) : e73.
  • 5Chirala SS, Jayakumar A, Gu ZW, et al. Human fatty acid synthase: role of interdomain in the for- mation of catalytically active synthase dimer [J].Proc Natl Acad Sci USA, 2001,98(6) :3104-3108.
  • 6Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes [J]. FASEB J, 1994, 8(15): 1248-1259.
  • 7Baron A, Migita T, Tang D, et al. Fatty acid syn- thase : a metabolic oncogene in prostate cancer[J] ? J Cell Biochem , 2004, 91(1): 47-53.
  • 8Visca P, Sebastiani V, Botti C, et al. Fatty acid synthase (FAS) is a marker of increased risk of re- currence in lung carcinoma [J]. Anticaneer Res, 2004, 24(6): 4169-4174.
  • 9Pizer E S, Pflug B R, Bova G S, et al. Increased fatty acid synthase as a therapeutic target in andro- gen - independent prostate cancer progression[J]. Prostate, 2001, 47(2): 102-110.
  • 10Milgraum LZ, Witters LA, Pasternaek G R, et aL Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma [J]. Clin Cancer Res, 1997, 3(11) : 2115-2120.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部